Salix Pharmaceuticals, a developer of medical devices and drugs for the prevention and treatment of gastrointestinal disorders, may be acquired for $190 per share, according to a Triangle Business Journal report.
Sterne Agee analysts predict there is a 55 percent probability that the company will be acquired at that price.
Salix Pharmaceuticals has been in contact with Allergan and Actavis for the discussion of a potential acquisition.
More articles on gastroenterology:
Dr. David Gottesman joins Cleveland Clinic
Are current endoscopy cleaning protocols enough?
Hudson Valley Hospital Center adds 2 gastroenterologists
Sterne Agee analysts predict there is a 55 percent probability that the company will be acquired at that price.
Salix Pharmaceuticals has been in contact with Allergan and Actavis for the discussion of a potential acquisition.
More articles on gastroenterology:
Dr. David Gottesman joins Cleveland Clinic
Are current endoscopy cleaning protocols enough?
Hudson Valley Hospital Center adds 2 gastroenterologists